Henry Ford recognized the utility of hemp in early times. In advance of today’s automobile manufacturers, he constructed a car with certain components made of resin stiffened with hemp fiber (Fig. 19). Rather ironically in view of today’s parallel situation, Henry Ford’s hemp innovations in the 1920s occurred at a time of crisis for American farms, later to intensify with the depression. The need to produce new industrial markets for farm products led to a broad movement for scientific research in agriculture that came to be labeled “Farm Chemurgy,” that today is embodied in chemical applications of crop constituents.
In 1976, Canadian botanist Ernest Small and American taxonomist Arthur Cronquist published a taxonomic revision that recognizes a single species of Cannabis with two subspecies: C. sativa L. subsp. sativa, and C. sativa L. subsp. indica (Lam.) Small & Cronq. The authors hypothesized that the two subspecies diverged primarily as a result of human selection; C. sativa subsp. sativa was presumably selected for traits that enhance fiber or seed production, whereas C. sativa subsp. indica was primarily selected for drug production. Within these two subspecies, Small and Cronquist described C. sativa L. subsp. sativa var. spontanea Vav. as a wild or escaped variety of low-intoxicant Cannabis, and C. sativa subsp. indica var. kafiristanica (Vav.) Small & Cronq. as a wild or escaped variety of the high-intoxicant type. This classification was based on several factors including interfertility, chromosome uniformity, chemotype, and numerical analysis of phenotypic characters.
Hemp hasn't always been on the wrong side of the authorities. The Puritans brought hemp with them to New England in 1645 and Europeans were growing it even earlier in Chile. George Washington planted hemp as one of several crops at his Mount Vernon estate. However, hemp's popularity waned in America as other plants used for textiles such as cotton and jute became more widely available. The U.S. Navy briefly campaigned for more hemp farming during World War II to supply ropes for ships. But the federal government continued restrictions on hemp after the war.
The Department has policies and procedures in place for the commonwealth's hemp research program, which can be found in the 2019 Pilot Program Parameters. Researchers from institutions of higher education or growers who would like to be considered for participation in the 2019 program must submit a 2019 PDA Industrial Hemp Research Pilot Program Permit Application prior to the application deadline of December 17, 2018. Researchers who participated in the 2018 Pilot Program may submit a Permit Renewal form by December 17, 2018 to continue their projects in the 2019 growing season.
Via CB1 receptor activation, THC indirectly increases dopamine release and produces psychotropic effects. Cannabidiol (CBD) also acts as an allosteric modulator of the μ- and δ-opioid receptors. THC also potentiates the effects of the glycine receptors. It is unknown if or how these actions contribute to the effects of cannabis.
According to the United Nations Office on Drugs and Crime (UNODC), "the amount of THC present in a cannabis sample is generally used as a measure of cannabis potency." The three main forms of cannabis products are the flower, resin (hashish), and oil (hash oil). The UNODC states that cannabis often contains 5% THC content, resin "can contain up to 20% THC content", and that "Cannabis oil may contain more than 60% THC content."
We gave the highest points to companies that use a CBD distillate for their tinctures. The process of distillation creates an extract that is pure on a molecular level. There are people who think distillate is too pure, and that a full spectrum decarb produces a more effective tincture. But in light of the inconclusive evidence, we prefer a distillate. The process allows for a high degree of control as to the finished product. It’s also odorless and tasteless, so those tinctures tend to taste better.
The genus Cannabis was first classified using the "modern" system of taxonomic nomenclature by Carl Linnaeus in 1753, who devised the system still in use for the naming of species. He considered the genus to be monotypic, having just a single species that he named Cannabis sativa L. (L. stands for Linnaeus, and indicates the authority who first named the species). Linnaeus was familiar with European hemp, which was widely cultivated at the time. In 1785, noted evolutionary biologist Jean-Baptiste de Lamarck published a description of a second species of Cannabis, which he named Cannabis indica Lam. Lamarck based his description of the newly named species on plant specimens collected in India. He described C. indica as having poorer fiber quality than C. sativa, but greater utility as an inebriant. Additional Cannabis species were proposed in the 19th century, including strains from China and Vietnam (Indo-China) assigned the names Cannabis chinensis Delile, and Cannabis gigantea Delile ex Vilmorin. However, many taxonomists found these putative species difficult to distinguish. In the early 20th century, the single-species concept was still widely accepted, except in the Soviet Union where Cannabis continued to be the subject of active taxonomic study. The name Cannabis indica was listed in various Pharmacopoeias, and was widely used to designate Cannabis suitable for the manufacture of medicinal preparations.
There is a general inverse relationship in the resin of Cannabis between the amounts of THC present and the amount of the other principal cannabinoid, CBD. Whereas most drug strains contain primarily THC and little or no CBD, fiber and oilseed strains primarily contain CBD and very little THC. CBD can be converted to THC by acid catalyzed cyclization, and so could serve as a starting material for manufacturing THC. In theory, therefore, low-THC cultivars do not completely solve the problem of drug abuse potential. In practice, however, the illicit drug trade has access to easier methods of synthesizing THC or its analogues than by first extracting CBD from non-drug hemp strains.
The main psychoactive constituent of Cannabis was identified as delta-9-tetrahydrocannabinol (THC). In 1986, an isomer of synthetic delta-9-THC in sesame oil was licensed and approved for the treatment of chemotherapy -associated nausea and vomiting under the generic name dronabinol. Clinical trials determined that dronabinol was as effective as or better than other antiemetic agents available at the time. Dronabinol was also studied for its ability to stimulate weight gain in patients with AIDS in the late 1980s. Thus, the indications were expanded to include treatment of anorexia associated with human immunodeficiency virus infection in 1992. Clinical trial results showed no statistically significant weight gain, although patients reported an improvement in appetite.[9,10] Another important cannabinoid found in Cannabis is CBD. This is a nonpsychoactive cannabinoid, which is an analog of THC.
"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia.
In 1937, the U.S. Treasury Department introduced the Marihuana Tax Act. This Act imposed a levy of $1 per ounce for medicinal use of Cannabis and $100 per ounce for nonmedical use. Physicians in the United States were the principal opponents of the Act. The American Medical Association (AMA) opposed the Act because physicians were required to pay a special tax for prescribing Cannabis, use special order forms to procure it, and keep special records concerning its professional use. In addition, the AMA believed that objective evidence that Cannabis was harmful was lacking and that passage of the Act would impede further research into its medicinal worth. In 1942, Cannabis was removed from the U.S. Pharmacopoeia because of persistent concerns about its potential to cause harm.[2,3]
Lisa Hamilton, a jeweler and doula in Brooklyn, NY, knows about the side effects. She recently tried CBD for the shoulder pain that plagued her five years after an accident. Her doctor certified that she was in chronic pain, which under New York State law allowed her to buy from a state dispensary. One Friday, she swallowed two 10-mg capsules, the amount recommended at the dispensary, then took another two on Saturday. “By Sunday, it felt like I’d gotten hit by a truck. Every muscle and joint ached,” Hamilton says. She cut back to one pill a day the following week, but still felt hungover. She stopped after that.
Health Tools Baby Due Date CalculatorBasal Metabolic Rate CalculatorBody Mass Index (BMI) CalculatorCalories Burned CalculatorChild Energy Requirements CalculatorDaily Calcium Requirements CalculatorDaily Fibre Requirements CalculatorIdeal Weight CalculatorInfectious Diseases Exclusion Periods ToolOvulation CalculatorSmoking Cost CalculatorTarget Heart Rate CalculatorWaist-to-hip Ratio Calculator Risk Tests Depression Self-AssessmentErectile Dysfunction ToolMacular Degeneration ToolOsteoporosis Risk TestProstate Symptoms Self-Assessment
I have digenerative disc disease/4 bulgin discs was taking 9---10mg hydrocodones a day... i started with 3 drops of 300mg and within 5 mins started feeling better than i have theses last 6 years or so... not only that, the inflamation has decrease substantially, i wake up with energy and have begun to work out again... if im making it seem like a miracle drug... its because it is... so the first week i took 3 drops twice a day... now 3 weeks in... im taking about 5 drops 3 times a day and zero pain pills... for the first time in years i have taken control of my life agin... not depending on doctor scripts/bills etc....